Athersys (NASDAQ:ATHX) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Shares of NASDAQ ATHX opened at $0.00 on Thursday. The stock has a market capitalization of $61,719.00, a price-to-earnings ratio of 0.00 and a beta of -0.90. Athersys has a 12-month low of $0.01 and a 12-month high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.